Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Liabilities (2016 - 2025)

Rocket Pharmaceuticals' Total Liabilities history spans 10 years, with the latest figure at $53.2 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 17.43% year-over-year to $53.2 million; the TTM value through Dec 2025 reached $53.2 million, down 17.43%, while the annual FY2025 figure was $53.2 million, 17.43% down from the prior year.
  • Total Liabilities for Q4 2025 was $53.2 million at Rocket Pharmaceuticals, down from $54.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $96.5 million in Q1 2021 and bottomed at $42.3 million in Q4 2021.
  • The 5-year median for Total Liabilities is $57.8 million (2023), against an average of $57.8 million.
  • The largest YoY upside for Total Liabilities was 46.87% in 2022 against a maximum downside of 55.92% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $42.3 million in 2021, then skyrocketed by 46.87% to $62.1 million in 2022, then rose by 18.75% to $73.8 million in 2023, then dropped by 12.61% to $64.5 million in 2024, then decreased by 17.43% to $53.2 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Total Liabilities are $53.2 million (Q4 2025), $54.4 million (Q3 2025), and $66.8 million (Q2 2025).